Literature DB >> 24477451

The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE).

Carlo Spreafico1, Marco Maccauro, Vincenzo Mazzaferro, Carlo Chiesa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24477451     DOI： 10.1007/s00259-013-2674-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

2.  Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

Authors:  Philip Hilgard; Monia Hamami; Amr El Fouly; André Scherag; Stefan Müller; Judith Ertle; Till Heusner; Vito R Cicinnati; Andreas Paul; Andreas Bockisch; Guido Gerken; Gerald Antoch
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

3.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

4.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Authors:  Raffaella Barone; Françoise Borson-Chazot; Roelf Valkema; Stéphan Walrand; Franck Chauvin; Lida Gogou; Larry K Kvols; Eric P Krenning; François Jamar; Stanislas Pauwels
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 6.  Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.

Authors:  Wan-Yee Lau; Bruno Sangro; Pier-Jer Chen; Shu-Qun Cheng; Pierce Chow; Rheun-Chuan Lee; Thomas Leung; Kwang-Hyub Han; Ronnie T P Poon
Journal:  Oncology       Date:  2013-04-18       Impact factor: 2.935

7.  A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.

Authors:  C Chiesa; M Mira; M Maccauro; R Romito; C Spreafico; C Sposito; S Bhoori; C Morosi; S Pellizzari; A Negri; E Civelli; R Lanocita; T Camerini; C Bampo; M Carrara; E Seregni; A Marchianò; V Mazzaferro; E Bombardieri
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 2.346

8.  Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment.

Authors:  Marta Cremonesi; Mahila Ferrari; Mirco Bartolomei; Franco Orsi; Guido Bonomo; Demetrio Aricò; Andrew Mallia; Concetta De Cicco; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-10       Impact factor: 9.236

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Authors:  E Garin; L Lenoir; J Edeline; S Laffont; H Mesbah; P Porée; L Sulpice; K Boudjema; M Mesbah; A Guillygomarc'h; E Quehen; M Pracht; J L Raoul; B Clement; Y Rolland; E Boucher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236
View more
  11 in total

1.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

2.  Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.

Authors:  C Chiesa; M Mira; M Maccauro; C Spreafico; R Romito; C Morosi; T Camerini; M Carrara; S Pellizzari; A Negri; G Aliberti; C Sposito; S Bhoori; A Facciorusso; E Civelli; R Lanocita; B Padovano; M Migliorisi; M C De Nile; E Seregni; A Marchianò; F Crippa; V Mazzaferro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

3.  Spatial density and tumor dosimetry are important in radiation segmentectomy with 90Y glass microspheres.

Authors:  Carlo Chiesa; Stefania Mazzaglia; Marco Maccauro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09       Impact factor: 10.057

4.  Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-17       Impact factor: 10.057

Review 5.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

6.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

7.  Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors.

Authors:  Alexandre Jadoul; Claire Bernard; Pierre Lovinfosse; Laurent Gérard; Henri Lilet; Olivier Cornet; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

Review 8.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08

9.  Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity.

Authors:  Jonas Högberg; Magnus Rizell; Ragnar Hultborn; Johanna Svensson; Olof Henrikson; Johan Mölne; Peter Gjertsson; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2015-04-25

Review 10.  Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.

Authors:  Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia
Journal:  Front Oncol       Date:  2014-08-19       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.